Chemed director receives 386-share stock award
CHEMED CORP director John Meredith Mount Jr. reported a compensation-related stock award of capital stock.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
CHEMED CORP director John Meredith Mount Jr. reported a compensation-related stock award of capital stock. He received 386 shares on May 18, 2026, described as an award of stock in the footnotes. The grant was valued at $440.77 per share for reporting purposes. After this award, his direct holdings increased to 1,316 shares of Chemed capital stock. This is a non-derivative, grant/award acquisition rather than an open-market purchase or sale.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Capital Stock | 386 | $440.77 | $170K |
Footnotes (1)
- F1. Award of stock
Key Figures
Key Terms
Grant, award, or other acquisition financial
Capital Stock financial
Award of stock financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did CHE director John Meredith Mount Jr. report?
Was the CHE Form 4 transaction a market buy or a stock award?
Does the CHE Form 4 show any stock sales or disposals by the director?
AI-generated analysis. How Rhea-AI works. Not financial advice.